Ibrance Trial Cements CDK4/6 Inhibitors As Standard Of Care In Breast Cancer

18 Nov 2016

• By Emily Hayes

New England Journal of Medicine editorial sings the praises of CDK4/6 inhibitors in breast cancer, which include Pfizer's Ibrance, Novartis's ribociclib and Elli Lilly's abemaciclib.

Full results for Pfizer Inc.'s cyclin-dependent kinase 4/6 inhibitor Ibrance in the confirmatory PALOMA-2 study cement the position of the class in the first-line treatment of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) breast cancer, with potential to move to the adjuvant and neoadjuvant settings.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Gilead Set To Expand Trodelvy/Keytruda Into Frontline TNBC

21 Apr 2025

• By Alaric DeArment

The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.

Enhertu Takes The First-Line Throne In HER2 Metastatic Breast Cancer

21 Apr 2025

• By Jessica Merrill

AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.

Oncology’s Most Eligible Unpartnered Assets

18 Apr 2025

• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

17 Apr 2025

• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.